Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, particularly in non-small-cell lung cancer (NSCLC), which has generated considerable interest and effort in developing ALK tyrosine kinase inhibitors (TKI). Crizotinib was the first ALK inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Geeta Geeta, Mota, Ines, Mologni, Luca, Patrucco, Enrico, Gambacorti-Passerini, Carlo, Chiarle, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876637/
https://www.ncbi.nlm.nih.gov/pubmed/29495603
http://dx.doi.org/10.3390/cancers10030062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876637/
https://www.ncbi.nlm.nih.gov/pubmed/29495603
http://dx.doi.org/10.3390/cancers10030062

Ejemplares similares